Literature DB >> 23539171

Lymphangioleiomyomatosis screening in women with tuberous sclerosis.

Corey J Cudzilo1, Rhonda D Szczesniak2, Alan S Brody3, Mantosh S Rattan3, Darcy A Krueger4, John J Bissler5, David N Franz4, Francis X McCormack1, Lisa R Young6.   

Abstract

BACKGROUND: Lymphangioleiomyomatosis (LAM) occurs in at least 40% of women with tuberous sclerosis complex (TSC), as diagnosed based on chest CT scan findings. Early identification may inform lifestyle choices and treatment decisions. Here we report LAM prevalence in a large TSC clinic and propose an approach to CT scan screening for LAM in women with TSC.
METHODS: We retrospectively reviewed initial chest CT scans of all female patients with TSC aged ≥ 15 years seen at our center over a 12-year period. Each CT image slice was manually scored for the presence or absence of characteristic thin-walled cysts, and the diagnosis of LAM was made if the sum of the cysts on all slices exceeded three cysts.
RESULTS: Of 133 female patients with TSC, 101 had chest CT scans available for review. Forty-eight (47.5%) met criteria for TSC-LAM on the initial CT scan. The risk of LAM was age dependent, rising by about 8% per year. The prevalence of LAM was 27% in subjects < 21 years of age and 81% in subjects > 40 years of age. Among asymptomatic subjects with LAM, 84% had cysts present in the single image at the level of the carina. Most subjects with LAM eventually developed pulmonary symptoms (63%), and 12.5% died from LAM.
CONCLUSIONS: These results suggest that most women with TSC ultimately develop cystic changes consistent with LAM and that most cases can be identified from a single CT imaging slice at the level of the carina. TSC-LAM was associated with appreciable morbidity and mortality in this referral population. An age-based approach using limited CT scanning methods may facilitate screening and subsequent treatment decisions with decreased radiation exposure in this at-risk population.

Entities:  

Mesh:

Year:  2013        PMID: 23539171     DOI: 10.1378/chest.12-2813

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  40 in total

1.  Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference.

Authors:  Hope Northrup; Darcy A Krueger
Journal:  Pediatr Neurol       Date:  2013-10       Impact factor: 3.372

Review 2.  Diffuse Cystic Lung Disease. Part I.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

3.  Apparent Sporadic Lymphangioleiomyomatosis in a Man as a Result of Extreme Mosaicism for a TSC2 Mutation.

Authors:  MeiLan K Han; Magdalena E Tyburczy; Thomas N Darling; Ella A Kazerooni; Jeffrey L Myers; Francis X McCormack; Joel Moss; David J Kwiatkowski
Journal:  Ann Am Thorac Soc       Date:  2017-07

Review 4.  The Genetics of Pneumothorax.

Authors:  Philip M Boone; Rachel M Scott; Stefan J Marciniak; Elizabeth P Henske; Benjamin A Raby
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

5.  Lymphangioleiomyomatosis Mortality in Patients with Tuberous Sclerosis Complex.

Authors:  Sara Zak; Nadine Mokhallati; Weiji Su; Francis X McCormack; David N Franz; Maxwell Mays; Darcy A Krueger; Rhonda D Szczesniak; Nishant Gupta
Journal:  Ann Am Thorac Soc       Date:  2019-04

Review 6.  Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

Authors:  Hen Prizant; Stephen R Hammes
Journal:  Endocrinology       Date:  2016-07-13       Impact factor: 4.736

7.  Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.

Authors:  Carmen Priolo; Stéphane J H Ricoult; Damir Khabibullin; Harilaos Filippakis; Jane Yu; Brendan D Manning; Clary Clish; Elizabeth P Henske
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

Review 8.  Pulmonary manifestations in tuberous sclerosis complex.

Authors:  Nishant Gupta; Elizabeth P Henske
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-07-28       Impact factor: 3.908

9.  [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM.

Authors:  Taylor R Kavanagh; William J Mischler; Eline E Verwer; You Feng; Kazue Takahashi; Shuyan Wang; Timothy M Shoup; Ramesh Neelamegam; Jing Yang; Nicolas J Guehl; Chongzhao Ran; Walter Massefski; Ye Cui; Souheil El-Chemaly; Peter M Sadow; William M Oldham; Marie F Kijewski; Georges El Fakhri; Marc D Normandin; Carmen Priolo
Journal:  Clin Cancer Res       Date:  2018-07-27       Impact factor: 12.531

10.  TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.

Authors:  Heng-Jia Liu; Patrick H Lizotte; Heng Du; Maria C Speranza; Hilaire C Lam; Spencer Vaughan; Nicola Alesi; Kwok-Kin Wong; Gordon J Freeman; Arlene H Sharpe; Elizabeth P Henske
Journal:  JCI Insight       Date:  2018-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.